
CLS Q4 - Paves the path for an exciting 2024

Redeye provides an update in relation to CLS' Q4 2023 report. Based on the report and the company's business update event, we make some estimate changes that both positively and negatively affect our valuation. However, we include a future capital raising to our model, diluting our fair value range with a base case of SEK0.3 (0.4).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[CLS Q4 - Paves the path for an exciting 2024](#)